Protective effects of C-type natriuretic peptide on cisplatin-induced nephrotoxicity in Mice

Cancer Chemotherapy and Pharmacology

Volumn 75, Issue 5, 2015, Pages 1057-1063

  Kimura, Toru ^a,b   Nojiri, Takashi ^a,b   Hosoda, Hiroshi ^a   Ishikane, Shin ^a   Shintani, Yasushi ^b   Inoue, Masayoshi ^b   Miyazato, Mikiya ^a   Okumura, Meinoshin ^b   Kangawa, Kenji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti inflammatory; C type natriuretic peptide; Cisplatin; Nephrotoxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CREATININE; NATRIURETIC PEPTIDE TYPE C;

ALBUMINURIA; ANIMAL; BLOOD; C57BL MOUSE; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG INTERACTION; GENE EXPRESSION; KIDNEY; KIDNEY DISEASES; MOUSE; PATHOLOGY; UREA NITROGEN BLOOD LEVEL; URINE;

ALBUMINURIA; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD UREA NITROGEN; CISPLATIN; CREATININE; DRUG INTERACTIONS; GENE EXPRESSION; KIDNEY; KIDNEY DISEASES; MICE; MICE, INBRED C57BL; NATRIURETIC PEPTIDE, C-TYPE;

EID: 84938696369     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-015-2734-7     Document Type: Article

References (37)

1. Arany I, Safirstein RL (2003) Cisplatin nephrotoxicity. Semin Nephrol 23:460-464
2. Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73:994-1007
3. Taguchi T, Nazneen A, Abid MR, Razzaque MS (2005) Cisplatin-associated nephrotoxicity and pathological events. Contrib Nephrol 148:107-121
4. Launay-Vacher V, Rey JB, Isnard-Bagnis C, Deray G, Daouphars M (2008) Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on cancer care. Cancer Chemother Pharmacol 61:903-909
5. Sudoh T, Minamino N, Kangawa K, Matsuo H (1990) C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 168:863-870
6. Langenickel TH, Buttgereit J, Pagel-Langenickel I, Lindner M, Monti J, Beuerlein K, Al-Saadi N, Plehm R, Popova E, Tank J, Dietz R, Willenbrock R, Bader M (2006) Cardiac hypertrophy in transgenic rats expressing a dominant-negative mutant of the natriuretic peptide receptor B. Proc Natl Acad Sci USA 103:4735-4740
7. Suga S, Nakao K, Itoh H, Komatsu Y, Ogawa Y, Hama N, Imura H (1992) Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of "vascular natriuretic peptide system". J Clin Invest 90:1145-1149
8. Kimura T, Nojiri T, Hosoda H, Ishikane S, Shintani Y, Inoue M, Miyazato M, Okumura M, Kangawa K (2014) C-type natriuretic peptide attenuates LPS-induced acute lung injury in mice. J Surg Res. doi: 10.1016/j.jss.2014.11.023
9. Itoh T, Nagaya N, Murakami S, Fujii T, Iwase T, Ishibashi-Ueda H, Yutani C, Yamagishi M, Kimura H, Kangawa K (2004) C-type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 170:1204-1211
10. Obata H, Yanagawa B, Tanaka K, Ohnishi S, Kataoka M, Miyahara Y, Ishibashi-Ueda H, Kodama M, Aizawa Y, Kangawa K, Nagaya N (2007) CNP infusion attenuates cardiac dysfunction and inflammation in myocarditis. Biochem Biophys Res Commun 356:60-66
11. Schachner T, Zou Y, Oberhuber A, Mairinger T, Tzankov A, Laufer G, Ott H, Bonatti J (2004) Perivascular application of C-type natriuretic peptide attenuates neointimal hyperplasia in experimental vein grafts. Eur J Cardiothorac Surg 25:585-590
12. Dean AD, Vehaskari VM, Ritter D, Greenwald JE (1996) Distribution and regulation of guanylyl cyclase type B in the rat nephron. Am J Physiol 270:F311-F318
13. Lohe A, Yeh I, Hyver T, Pratt R, Jamison R (1995) Natriuretic peptide B receptor and C-type natriuretic peptide in the rat kidney. J Am Soc Nephrol 6:1552-1558
14. Canaan-Kuhl S, Ostendorf T, Zander K, Koch KM, Floege J (1998) C-type natriuretic peptide inhibits mesangial cell proliferation and matrix accumulation in vivo. Kidney Int 53:1143-1151
15. Segawa K, Minami K, Jimi N, Nakashima Y, Shigematsu A (1998) C-type natriuretic peptide inhibits rat mesangial cell proliferation by a phosphorylation-dependent mechanism. Naunyn Schmiedebergs Arch Pharmacol 357:70-76
16. Nojiri T, Hosoda H, Kimura T, Miura K, Ishikane S, Tokudome T, Shintani Y, Inoue M, Miyazato M, Okumura M, Kangawa K (2014) Atrial natriuretic peptide protects against cisplatin-induced acute kidney injury. Cancer Chemother Pharmacol. doi: 10.1007/s00280-014-2624-4
17. Ramesh G, Reeves WB (2002) TNF-alpha mediates chemokine and cytokine expression and renal injury in cisplatin nephrotoxicity. J Clin Invest 110:835-842
18. Takahashi A, Kimura T, Takabatake Y, Namba T, Kaimori J, Kitamura H, Matsui I, Niimura F, Matsusaka T, Fujita N, Yoshimori T, Isaka Y, Rakugi H (2012) Autophagy guards against cisplatin-induced acute kidney injury. Am J Pathol 180:517-525
19. Lee KW, Jeong JY, Lim BJ, Chang YK, Lee SJ, Na KR, Shin YT, Choi DE (2009) Sildenafil attenuates renal injury in an experimental model of rat cisplatin-induced nephrotoxicity. Toxicology 257:137-143
20. Lau AH (1999) Apoptosis induced by cisplatin nephrotoxic injury. Kidney Int 56:1295-1298
21. Lameire NH, Bagga A, Cruz D, De Maeseneer J, Endre Z, Kellum JA, Liu KD, Mehta RL, Pannu N, Van Biesen W, Vanholder R (2013) Acute kidney injury: an increasing global concern. Lancet 382:170-179
22. Ichimura T, Hung CC, Yang SA, Stevens JL, Bonventre JV (2004) Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 286:F552-F563
23. McIlroy DR, Wagener G, Lee HT (2010) Biomarkers of acute kidney injury: an evolving domain. Anesthesiology 112:998-1004
24. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P (2004) Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 24:307-315
25. Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of Cisplatin nephrotoxicity. Toxins 2:2490-2518
26. Sangaralingham SJ, Heublein DM, Grande JP, Cataliotti A, Rule AD, McKie PM, Martin FL, Burnett JC Jr (2011) Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging. Am J Physiol Renal physiol 301:F943-F952
27. Igaki T, Itoh H, Suga S, Hama N, Ogawa Y, Komatsu Y, Mukoyama M, Sugawara A, Yoshimasa T, Tanaka I, Nakao K (1996) C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int Suppl 55:S144-S147
28. Lewko B, Endlich N, Kriz W, Stepinski J, Endlich K (2004) C-type natriuretic peptide as a podocyte hormone and modulation of its cGMP production by glucose and mechanical stress. Kidney Int 66:1001-1008
29. Kiemer AK, Lehner MD, Hartung T, Vollmar AM (2002) Inhibition of cyclooxygenase-2 by natriuretic peptides. Endocrinology 143:846-852
30. Maimaitiyiming H, Li Y, Cui W, Tong X, Norman H, Qi X, Wang S (2013) Increasing cGMP-dependent protein kinase I activity attenuates cisplatin-induced kidney injury through protection of mitochondria function. Am J Physiol Renal Physiol 305:F881-F890
31. Whitaker RM, Wills LP, Stallons LJ, Schnellmann RG (2013) cGMP-selective phosphodiesterase inhibitors stimulate mitochondrial biogenesis and promote recovery from acute kidney injury. J Pharmacol Exp Ther 347:626-634
32. Kim CS, Choi JS, Park JW, Bae EH, Ma SK, Lee J, Kim SW (2012) Altered regulation of nitric oxide and natriuretic peptide system in cisplatin-induced nephropathy. Regul Pept 174:65-70
33. Ahluwalia A, MacAllister RJ, Hobbs AJ (2004) Vascular actions of natriuretic peptides. Cyclic GMP-dependent and -independent mechanisms. Basic Res Cardiol 99:83-89
34. Del Ry S (2013) C-type natriuretic peptide: a new cardiac mediator. Peptides 40:93-98
35. Canaan-Kuhl S, Jamison RL, Myers BD, Pratt RE (1992) Identification of "B" receptor for natriuretic peptide in human kidney. Endocrinology 130:550-552
36. Pham I, Sediame S, Maistre G, Roudot-Thoraval F, Chabrier PE, Carayon A, Adnot S (1997) Renal and vascular effects of C-type and atrial natriuretic peptides in humans. Am J Physiol 273:R1457-R1464
37. Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr (2013) Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J 34:886-893